Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

AIDS. 2005 Jan 3;19(1):97-9. doi: 10.1097/00002030-200501030-00014.

Abstract

Genetic (human leukocyte antigen), disease-related and demographic risk factors for nevirapine reactions were examined in a nevirapine-exposed cohort. Cases involving combinations of hepatitis, fever or rash were associated with an interaction between HLA-DRB1*0101 and the percentage of CD4, whereas no associations were detected for isolated rash. These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cohort Studies
  • Drug Hypersensitivity / genetics*
  • Drug Hypersensitivity / immunology
  • Female
  • Genetic Predisposition to Disease / genetics*
  • HLA Antigens / genetics
  • HLA Antigens / immunology
  • HLA-A Antigens / genetics*
  • HLA-A Antigens / immunology
  • HLA-DRB1 Chains
  • Humans
  • Immunity, Cellular / genetics
  • Immunity, Cellular / immunology
  • Male
  • Nevirapine / adverse effects*
  • Reverse Transcriptase Inhibitors / adverse effects*

Substances

  • HLA Antigens
  • HLA-A Antigens
  • HLA-DRB1 Chains
  • HLA-DRB1*01:01 antigen
  • Reverse Transcriptase Inhibitors
  • Nevirapine